EverSource Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

EverSource Wealth Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$86.5K	Buy	512 +166	+48%	+$28.7K	﹤0.01%	1523
2025 Q4	$63.2K	Sell	346 -9	-3%	-$1.26K	﹤0.01%	1594
2025 Q3	$43.1K	Buy	355 +41	+13%	+$4.62K	﹤0.01%	1805
2025 Q2	$32.8K	Buy	314 +55	+21%	+$5.82K	﹤0.01%	1922
2025 Q1	$30.2K	Buy	259 +81	+46%	+$9.23K	﹤0.01%	1476
2024 Q4	$15.1K	Buy	178 +58	+48%	+$5.33K	﹤0.01%	1784
2024 Q3	$10.8K	Buy	120 +2	+2%	+$175	﹤0.01%	1819
2024 Q2	$10.3K	Buy	118 +99	+521%	+$7.33K	﹤0.01%	1840
2024 Q1	$1.4K	Sell	19 -43	-69%	-$3.61K	﹤0.01%	2480
2023 Q4	$4.93K	Buy	+62	New	+$4.14K	﹤0.01%	1866

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverSource Wealth Advisors's AXSM Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Axsome Therapeutics (AXSM) stake by 48% in Q1 2026, buying an estimated $28.7K and bringing the position to 512 shares worth $86.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1523.

EverSource Wealth Advisors first reported a position in AXSM in Q4 2023 and has held it in 10 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

EverSource Wealth Advisors held 512 shares of Axsome Therapeutics worth $86.5K as of Q1 2026.
EverSource Wealth Advisors bought 166 Axsome Therapeutics shares in Q1 2026, an estimated $28.7K.
Axsome Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #1523 holding.
EverSource Wealth Advisors first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 10 quarters since.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.